Patents by Inventor Jens Buchardt

Jens Buchardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20200306382
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Application
    Filed: April 28, 2020
    Publication date: October 1, 2020
    Applicant: Novo Nordisk HealthCare AG
    Inventors: Henrik Sune Andersen, Nils Langeland Johansen, Jens Buchardt, Leif Noerskov-Lauritsen
  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20200102568
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 2, 2020
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20190203213
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 4, 2019
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20180221501
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Application
    Filed: December 18, 2017
    Publication date: August 9, 2018
    Inventors: Henrik Sune Andersen, Nils Langeland Johansen, Jens Buchardt, Leif Noerskov-Lauritsen
  • Antagonistic DR3 Ligands
    Publication number: 20170305994
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: July 5, 2017
    Publication date: October 26, 2017
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20170239362
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.
    Type: Application
    Filed: May 4, 2017
    Publication date: August 24, 2017
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Antagonistic DR3 ligands
    Patent number: 9737612
    Abstract: The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: August 22, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Albrecht Gruhler, Susanne Nedergaard Grell, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Antagonistic DR3 ligands
    Patent number: 9713644
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: July 25, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Growth hormones with prolonged in-vivo efficacy
    Patent number: 9695226
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: July 4, 2017
    Assignee: Novo Nordisk HealthCare AG
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Factor VIII Molecules with Reduced VWF Binding
    Publication number: 20170020992
    Abstract: The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group.
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Inventors: Gert Bolt, Bernd Peschke, Mikael Kofod-Hansen, Jens Buchardt, Henning Ralf Stennicke, Henrik Oestergaard, Marianne Kjalke, Eva H. Norling Olsen, Jens Jacob Hansen, Magali Zundel
  • Targeted Delivery of Factor VIII Proteins to Platelets
    Publication number: 20160251409
    Abstract: The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.
    Type: Application
    Filed: May 19, 2016
    Publication date: September 1, 2016
    Inventors: Henrik Oestergaard, Anthony Pusateri, Thomas R. Barnett, Jens Buchardt, Bernd Peschke, Mikael Kofod-Hansen, Magali A. Zundel, Carsten Behrens, Eva H. Norling Olsen, Henning Stennicke
  • THROMBIN SENSITIVE COAGULATION FACTOR X MOLECULES
    Publication number: 20160024487
    Abstract: The present invention relates to thrombin sensitive coagulation Factor X (FX), as well as use thereof in medicine. In particular the invention relates to FX molecules comprising 2 to 10 amino acid modifications in the activation peptide N-terminally of the FX “IVGG” motif as well as compositions comprising such molecules and use thereof. Such molecules may be useful in connection with convenient and patient friendly treatment regimens in treatment and prophylaxis of haemophilia.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 28, 2016
    Applicant: NOVO NORDISK A/S
    Inventors: Jens J. Hansen, Jens Breinholt, Jens Buchardt, Kristoffer Winther Balling, Prafull S. Gandhi, Henrik Oestergaard, Grant E. Blouse
  • Conjugated proteins
    Patent number: 9234192
    Abstract: The present invention relates to modified therapeutic proteins, such as e.g. coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules such as e.g. FVII, FVIII, or FIX comprising a hydrophobic side group.
    Type: Grant
    Filed: February 9, 2011
    Date of Patent: January 12, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Jens Buchardt, Carsten Behrens
  • Factor VIII Molecules With Reduced VWF Binding
    Publication number: 20150376262
    Abstract: The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group.
    Type: Application
    Filed: September 11, 2015
    Publication date: December 31, 2015
    Inventors: Bernd Peschke, Mikael Kofod-Hansen, Jens Buchardt, Henning Ralf Stennicke, Henrik Oestergaard, Marianne Kjalke, Eva H. Norling Olsen, Olsen, Jens Jacob Hansen
  • Conjugated FVIII variants
    Patent number: 9018166
    Abstract: The present invention relates to conjugated Factor VIII variants. The present invention in particular relates to conjugated FVIII variants comprising different polymeric groups as well as use thereof.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: April 28, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Carsten Behrens, Jens Buchardt, Magali Zundel
  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20140329750
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventors: Henrik Sune Andersen, Nils Langeland Johansen, Jens Buchardt, Leif Noerskov-Lauritsen
  • ANTAGONISTIC DR3 LIGANDS
    Publication number: 20140294853
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: May 1, 2014
    Publication date: October 2, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Growth hormones with prolonged in-vivo efficacy
    Patent number: 8841249
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: September 23, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Nils Langeland Johansen, Henrik Sune Andersen, Jens Buchardt, Leif Norskov-Lauritsen
  • Antagonistic DR3 ligands
    Patent number: 8765130
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: July 1, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20140107324
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.
    Type: Application
    Filed: December 18, 2013
    Publication date: April 17, 2014
    Applicant: Novo Nordisk Health Care AG
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt